GlycoDisplay Aps develops novel biopharmaceuticals by modifying sugars. The proprietary technology applies targeted cell engineering to display different glycans on cells and proteins. GlycoDisplay is a spin-out from University of Copenhagen, Center for Glycomics, which is world leading within the field of glyco-engineering and glycomics. The Glycodisplay business model focuses on specific drug programs where glyco-optimized leads are identified either internally or in close collaboration with pharmaceutical companies.